To view the press release in its entirety, click here. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice, and building the foundation for a healthier society. The Numinus Wellness model – including psychedelic production, supply, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance abuse. Numinus Wellness Inc ( CVE:NUMI) ( OTCMKTS:LKYSF) ( FRA:LR23) announced it had received Health Canada approval for the MAPS-sponsored open label study of MDMA-assisted therapy for post-traumatic stress disorder (PTSD). Numinus Wellness (TSX-V NUMI) empowers people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. A copy of the Warrant Indenture is available under the Company’s SEDAR profile at In addition, the Company announces that the trading symbol for its previously listed common share purchase warrants trading under the symbol “NUMI.WS” will change to “NUMI.WT.B” effective at market open on Monday, April 26, 2021.
The Warrants were issued pursuant to, and are governed by, the terms of a warrant indenture dated March 19, 2021 (the “ Warrant Indenture“) between the Company and Odyssey Trust Company. The Warrants will be listed for trading on the TSXV under the symbol “NUMI.WT.C” effective at market open on Tuesday, April 27, 2021.Įach Warrant entitles the holder thereof to acquire one common share of the Company at an exercise price of $1.75 until March 19, 2023.
This list allows interested parties to acquire the details of vulnerabilities by referring to a unique identifier known as the CVE ID.
Cve numi software#
Numinus Wellness Inc.( CVE:NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that the TSX Venture Exchange (“ TSXV“) has accepted for listing the 16,100,000 common share purchase warrants (the “ Warrants“) issued pursuant to the Company’s previously announced prospectus offering that closed on March 19, 2021. The Common Vulnerabilities and Exposures (CVE) program is a dictionary or glossary of vulnerabilities that have been identified for specific code bases, such as software applications or open libraries.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
0 kommentar(er)
